

1. **Ostertag, W., and Muller, H.J.:** Genetic basis of somatic damage produced by radiation. *Science* **130**, 1422-1423 (1958), and "Studies in Genetics" (H.J. Muller, ed.), p. 427 (1962).
2. **Ostertag, W.:** The genetic basis of somatic damage produced by radiation in third instar larvae of Drosophila melanogaster. I. Death before maturity. *Z. Vererbungslehre* **94**, 143-162 (1963).
3. **Ostertag, W., Themann, H., und Duisberg, E.:** Die Induktion von Ferritin in normalen menschlichen Zellkulturen nach Zugabe von Eisen(II)-sulfat. *Z. Menschl. Vererb.-u. Konstitutionslehre* **37**, 534-548 (1964).
4. **Ostertag, W.:** The change in ploidy of human cells in culture after temperature shock. *Exp. Cell Res.* **34**, 194-198 (1964).
5. **Ostertag, W., Duisberg, E., and Stürmann, M.:** Concerning the mutagenic activity of caffeine in man. *Mutation Res.* **2**, 293-296 (1965).
6. **Ostertag, W., and Kersten, W.:** The action of proflavin and actinomycin D in causing chromatid breakage in human cells. *Exp. Cell Res.* **39**, 296-301 (1965).
7. **Ostertag, W.:** Chemische Mutagenese an menschlichen Zellen in Kultur. *Habilitations-schrift Münster*, 1965. Abhandlungen der Mainzer Akademie der Wissenschaften und der Literatur. 124 Seiten.
8. **Ostertag, W.:** Koffein- und Theophyllinmutagenese bei Zell- und Leukozytenkulturen des Menschen. *Mutation Res.* **3**, 249-267 (1966).
9. **v. Verschuer, O., und Ostertag, W.:** Mutationsforschung am Menschen. Landesamt für Forschung. Jahrbuch 1966. Westd. Verlag, Köln und Opladen, S. 655-677.
10. **Ostertag, W., and Haake, J.:** The mutagenicity in Drosophila melanogaster of caffeine and other compounds which produce chromosome breakage in human cells in culture. *Z. Vererbungslehre* **98**, 299-308 (1966).
11. **Ostertag, W., und Fromme, H.G.:** Morphologische und chromosomale Veränderungen an Leukozyten- und HeLa-Zellkulturen des Menschen und Chromosomenverlust bei Drosophila melanogaster nach Koffeinapplikation. *Vortrag, Gesellschaft für Anthropologie und Gesellschaft für Konstitutionsforschung, Freiburg*, Oktober 1965, S. 176-186 (1967).
12. **Ostertag, W., und Greif, B.J.:** Die Erzeugung von Chromatidenbrüchen durch Coffein in Leukozytenkulturen des Menschen. *Humangenetik* **3**, 282-294 (1967).
13. **Kuhlmann, W., Fromme, H.G., Heege, E.H., and Ostertag, W.:** The mutagenic action of caffeine in higher organisms. *Cancer Res.* **28**, 2315-2389 (1968).
14. **Ostertag, W., and Smith, E.W.:** Hb Sinai, a new alpha chain mutant alpha his 47. *Humangenetik* **6**, 377-379 (1968).
15. **Kuhlmann, W., Themann, H., and Osterta, W.:** Differentiation of rabbit blastocysts in vitro. *Z. Mikroskop.-anatom. Forsch.* **79**, 573-585 (1968).
15. **Ostertag, W., and Smith, E.W.:** Hemoglobin-Lepore-Baltimore, a third type of a δ - β crossover ($\delta 50$, $\beta 86$). *Eur. J. Biochem.* **10**, 371-376 (1969).

16. **Charache, S., and Ostertag, W.:** Hemoglobin Hopkins-2 (α -112 Asp₂β₂): "low-output" protects from potentially harmful effects. *Blood* **36**, 852 (1970).
18. **Steinheider, G., Melderis, H., and Ostertag, W.:** Mammalian embryonic hemoglobins. In: *International Symposium, Synthesis, Structure and Function of Hemoglobin, Bad Nauheim* (H. Martin and L. Novicki, eds), pp. 225-235 (1971).
19. **Charache, S., Ostertag, W., and v. Ehrenstein, G.:** Hopkins-2 hemoglobin: clinical studies and physiological properties. *Nature* **234**, 248-250 (1971), revised: *Nature* **237**, 88-90 (1972).
20. **Ostertag, W., v. Ehrenstein, G., and Charache, S.:** Duplicated alpha-chain genes in Hopkins-2 haemoglobin of man and evidence for unequal crossing over between them. *Nat New Biol.* **237**(72), 90-4 (1972)
21. **Ostertag, W., Melderis, H., Steinheider, G., Kluge, N., and Dube, S.K.:** Synthesis of mouse hemoglobin and globin mRNA in leukaemic cell cultures. *Nature* **239**, 231-234 (1972).
22. **Ostertag, W., Crozier, T., Kluge, N., Melderis, H., and Dube, S.K.:** The action of 5-bromodesoxyuridine on the induction of hemoglobin synthesis in mouse leukemia cells sensitive and resistant to 5-BUdR. *Nature* **243**, 203-205 (1973).
23. **Ostertag, W., Gaedicke, G., Kluge, N., Melderis, H., Weimann, B., and Dube, S.K.:** Globin messenger in mouse leukemic cells: activity associated with RNA species in the region of 8 to 16S. *FEBS Letters* **32**, 218-222 (1973).
24. **Ostertag, W., und Kluge, N.:** Genetische Untersuchung zur Hämoglobin-bildung bei Hämoglobinopathien und bei der Erythroleukämie. *Berichte der Physico-Medica, Würzburg* **81**, 89-98 (1973).
25. **Maisel, J., Klement, U., Lai, M.M-C., Ostertag, W., and Duesberg, P.:** Ribonucleic acid components of murine sarcoma and leukemia viruses. *Proc. Natl. Acad. Sci. USA* **70**, 3536-3540 (1973).
25. **Weimann, B.J., Kluge, N., Cole, T., Dube, S.K., v. Ehrenstein, G., Gaedicke, G., Kind, J., Knebel, A., Krieg, J.C., Melderis, H., and Ostertag, W.:** Differentiation and transformation of hemopoietic cells in culture. In: *Modern Trends in Human Leukemia* (R. Neth, R. Gallo, F. Stohlman, and S. Spiegelman, eds), pp. 84-93. Grune and Stratton, New York, 1974.
27. **Gaedicke, G., Abedin, Z., Dube, S.K., Kluge, N., Neth, R., Steinheider, G., Weimann, B.J., and Ostertag, W.:** Control of globin synthesis during DMSO induced differentiation of mouse erythroleukemic cells in culture. In: *Modern Trends in Human Leukemia* (R. Neth, R. Gallo, F. Stohlman, and S. Spiegelman, eds), pp. 278-287. Grune and Stratton, New York, 1974.
28. **Ostertag, W., Cole, T., Crozier, T., Gaedicke, G., Kluge, N., Kind, J., Krieg, C., Roesler, G., Steinheider, G., Weimann, B., and Dube, S.K.:** Viral involvement in differentiation of erythroleukemic mouse and human cells. In: *Symposium on Differentiation and Control of Malignancy of Tumor Cells, Tokyo, 1973*, pp. 493-520 (1974).
29. **Dube, S.K., Gaedicke, G., Kluge, N., Weimann, B., Melderis, H., Steinheider, G., Crozier, T., Beckmann, H., and Ostertag, W.:** Hemoglobin synthesizing mouse and human erythroleukemic cell lines as model systems for the study of differentiation and control of gene expression. In: *Symposium on Differentiation and Control of Malignancy of Tumor Cells, Tokyo, 1973*, pp. 103-136 (1974).
30. **Melderis, H., Steinheider, G., and Ostertag, W.:** Evidence for a unique kind of a-type globin chain in early mammalian embryos. *Nature* **250**, 774-776 (1974).

31. **Swetly, P., and Ostertag, W.:** Effect of interferon on release of Friend virus and on DMSO induced stimulation of hemoglobin synthesis in erythroleukemic cells in culture. *Nature* **251**, 642-644 (1974).
32. **Kluge, N., Gaedicke, G., Steinheider, G., Dube, S., and Ostertag, W.:** Globin synthesis in Friend-erythroleukemia mouse cells in protein- and lipid-free medium. *Exp. Cell Res.* **88**, 257-262 (1974).
33. **Ostertag, W., Roesler, G., Krieg, C.J., Kind, J., Cole, T., Crozier, T., Gaedicke, G., Steinheider, G., Kluge, N., and Dube, S.K.:** Induction of endogenous virus and of Thymidine kinase by Bromodeoxyuridine in cell cultures transformed by Friend virus. *Proc. Natl. Acad. Sci. USA* **71**, 4980-4985 (1974).
34. **Preusser, A., Furusawa, M., Kluge, N., Steinheider, G., Dube, S.K., and Ostertag, W.:** Simulation of thalassemia in erythroleukemia cells in culture. *In: Symposium on Abnormal Hemoglobins and Thalassemia (M. Aksoy, ed.)*, Istanbul 1974, pp. 225-236 (1975).
35. **Dube, S.K., Pragnell, I.B., Kluge, N., Gaedicke, G., Steinheider, G., and Ostertag, W.:** Induction of endogenous and of spleen focus forming virus during DMSO induced differentiation of spleen focus forming virus transformed cells. *Proc. Natl. Acad. Sci. USA* **72**, 1863-1867 (1975).
36. **Steinheider, G., Melderis, H., and Ostertag, W.:** Evidence for Hb Lepore-like hybrid e globin genes in mice. *Nature* **257**, 712-714 (1975).
37. **Steinheider, G., Melderis, H., and Ostertag, W.:** Embryonic a chains of mice and rabbits. *Nature* **257**, 714-716 (1975).
38. **Weimann, B.J., Kluge, N., Dube, S.K., von Ehrenstein, G., Krieg, J.C., Kind, J., and Ostertag, W.:** Particle-associated RNA-dependent DNA polymerase and high-molecular-weight RNA in a human cell line derived from polycythemia vera bone marrow. *J. Natl. Cancer Inst.* **55**, 537-541 (1975).
39. **Gross, H.J., Stephens, E., Jungwirth, C., Winkler, G., Hiller, G., Bermeyer, G., Viehhauser, G., Bodo, G., Ostertag, W., and Dube, S.K.:** Translation of viral and cellular mRNAs in extracts from interferon treated cells. *INSERM* **47**, 373-378 (1975).
40. **Weimann, B.J., Schmidt, J., Kluge, N., Ostertag, W., and Wolfrum, D.J.:** RNA dependent DNA polymerase from a cell line derived from the bone marrow of a patient with polycythaemia vera. *Eur. J. Biochem.* **59**, 581-588 (1975).
41. **Hiller, G., Winkler, G., Viehauser, G., Jungwirth, C., Bodo, G., Dube, S.K., and Ostertag, W.:** Failure of globin mRNA to stimulate globin synthesis in cell-free extracts of interferon treated globin synthesizing mouse erythroleukemic cells. *Virology* **69**, 360-363 (1976).
42. **Pragnell, I.B., Ostertag, W., Harrison, P.R., Williamson, R., and Paul, J.:** Regulation of erythroid differentiation in normal and leukemic cells. *In: 2nd International Conference on Differentiation*, Copenhagen 1975, pp. 501-511 (1976).
43. **Kluge, N., Ostertag, W., Sugiyama, T., Jovin-Arndt, D., Steinheider, G., Furusawa, M., and Dube, S.K.:** DMSO induced differentiation and hemoglobin synthesis in tissue cultures of 7, 12-DMBA transformed rat erythroleukemia cells. *Proc. Natl. Acad. Sci. USA* **73**, 1237-1240 (1976).
44. **Arndt-Jovin, D., Ostertag, W., Eisen, H., Klimek, F., and Jovin, T.M.:** Studies of cellular differentiation by automated cell separation. Two model systems: Friend virus transformed cells and *Hydra attenuata*. *J. Histochem. Cytochem.* **24**, 332-347 (1976).
45. **Dube, S.K., Kung, H.J., Bender, W., Davidson, N., and Ostertag, W.:** Size, subunit composition and secondary structure of the Friend virus genome. *J. Virol.* **20**, 264-272 (1976).

46. **Arndt-Jovin, D., Ostertag, W., Eisen, H., and Jovin, T.:** Analysis by computer-controlled cell sorter of Friend virus-transformed cells in different stages of differentiation. *In: Modern Trends in Human Leukemia (R. Neth et al., eds)*, pp. 137-149. Grune and Stratton, New York, 1976.
47. **Swetly, P., and Ostertag, W.:** Interferon: action and induction in Friend transformed erythroleukemic cells during erythropoietic differentiation. *In: Molecular Basis of Malignancy (E. Deutsch et al., eds)*, pp. 80-85. Georg Thieme, Stuttgart, 1976.
48. **Eisen, H., Nasi, S., Georgopoulos, C.P., Arndt-Jovin, D., and Ostertag, W.:** Surface changes in differentiation of Friend erythroleukemic cells in culture. *Cell* **10**, 689-695 (1977).
49. **Pragnell, I.B., Ostertag, W., and Paul, J.:** The expression of viral and globin genes during differentiation of the Friend cell. *Exp. Cell Res.* **108**, 269-278 (1977).
50. **Eisen, H., Furusawa, M., Tanabe, K., Takada, S., and Ostertag, W.:** Interactions of rodent malarial parasites with Friend erythroleukemia cells in vitro. *Bull. World Hlth Org.* **55**, 367-372 (1977).
51. **Krieg, C.J., Ostertag, W., Pragnell, I., Swetly, P., Roesler, G., Cole, T., and Weimann, B.J.:** Increase in intracisternal A type particles in Friend cells during inhibition of Friend virus (SFFV) release by interferon of azidothymidine. *Exp. Cell Res.* **116**, 21-29 (1978).
52. **Ostertag, W., Krieg, C.J., Cole, T., Pragnell, I.B., Swetly, P., Weimann, B.J., and Dube, S.K.:** Induction of intracisternal A type particles during Friend cell differentiation. *Exp. Cell Res.* **116**, 31-37 (1978).
53. **Ostertag, W., and Pragnell, I.B.:** Changes in genome composition of the Friend virus complex in erythroleukemia cells during the course of DMSO induced differentiation. *Proc. Natl. Acad. Sci. USA* **75**, 3278-3282 (1978).
54. **Pragnell, I.B., McNab, A., Harrison, P.R., and Ostertag, W.:** Are spleen focus forming virus sequences related to xenotropic viruses and expressed specifically in normal erythroid cells? *Nature* **272**, 456-458 (1978).
55. **Sassa, S., Granick, J.L., Eisen, H., and Ostertag, W.:** Regulation of heme biosynthesis in mouse Friend-virus transformed cells in culture. *In: In Vitro Aspects of Erythropoiesis (M.J. Murphy, ed.)*, pp. 135-142. Springer, 1978.
56. **Sassa, S., Granick, J.L., Eisen, H., and Ostertag, W.:** Materials and methods for mouse Friend virus-infected cells. *In: In Vitro Aspects of Erythropoiesis (M.J. Murphy, ed.)*, pp. 268-270. Springer, 1978.
57. **Eisen, H., Keppel-Ballivet, F., Georgopoulos, C.P., Sassa, S., Granick, J.L., Pragnell, I.B., and Ostertag, W.:** Biochemical and genetic analysis of erythroid differentiation in Friend virus transformed murine erythroleukemia cells. *In: Cold Spring Harbor Conference on Cell Proliferation (B. Clarkson et al., eds)*, Vol. 5, pp. 277-294. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1978.
58. **Pragnell, I.B., Harrison, P.R., and Ostertag, W.:** Characterization of the Friend virus genome. *In: Oncogenic Viruses and Host Cell Genes (Y. Ikawa, ed.)*, pp. 173-208. Academic Press, New York, 1979.
59. **Ostertag, W., Pragnell, I.B., Arndt-Jovin, D., and Eisen, H.:** The Friend virus during Friend cell differentiation. *In: Oncogenic Viruses and Host Cell Genes (Y. Ikawa, ed.)*, pp. 195-208. Academic Press, New York, 1979.
60. **Pragnell, I.B., Ostertag, W., Paul, J., and Williamson, R.:** The Friend virus genome: partial characterization of a complete DNA copy. *J. Gen. Virol.* **43**, 1-14 (1979).

61. **Pragnell, I.B., Arndt-Jovin, D., Jovin, T., Fagg, B., and Ostertag, W.:** Commitment to differentiation in Friend cells and initiation of globin mRNA synthesis occurs during the G1 phase of the cell cycle. *Exp. Cell Res.* **125**, 459-470 (1980).
62. **Ostertag, W., Vehmeyer, K., Fagg, B., Pragnell, I.B., Paetz, W., LeBousse, M.C., Smadja-Joffe, F., Klein, B., Jasmin, C., and Eisen, H.:** Myeloproliferative virus, a cloned murine sarcoma virus with spleen-focus forming properties in adult mice. *J. Virol.* **33**, 573-582 (1980).
63. **Greenberger, J.S., Eckner, R.J., Ostertag, W., Colletta, G., Boschetti, S., Nagasawa, H., Karpas, A., Weichselbaum, R.R., and Moloney, W.C.:** Release of spleen focus-forming virus (SFFV) from differentiation inducible promyelocytic leukemia cell lines transformed in vitro by Friend leukemia virus. *Virology* **105**, 425-435 (1980).
64. **Bilello, J., Colletta, G., Warnecke, G., Koch, G., Frisby, D., Pragnell, I.B., and Ostertag, W.:** Analysis of the expression of spleen focus-forming virus (SFFV)-related RNA and gp55, a Friend and Rauscher virus-specific protein. *Virology* **107**, 331-344 (1980).
65. **Frisby, D., Colletta, G., Pragnell, I.B., Ostertag, W., Bilello, J., Warnecke, G., and Koch, G.:** SFFV specific gene expression in infected and erythroleukemia cells. In: *ICN UCLA Symposium on Molecular Cellular Biology, Vol. 18*, pp. 411-423 (1980).
66. **Fagg, B., Vehmeyer, K., Ostertag, W., Jasmin, C., and Klein, B.:** Modified erythropoiesis in mice infected with the anemia or polycythemia-producing strains of Friend virus or with myeloproliferative virus. In: *In Vivo and In Vitro Erythropoiesis: The Friend System (G.B. Rossi, ed.)*, pp. 163-172. Elsevier/North Holland, Amsterdam, 1980.
67. **Jasmin, C., LeBousse, M.C., Klein, B., Smadja-Joffe, F., Mori, K.J., Fagg, B., Ostertag, W., Vehmeyer, K., and Pragnell, I.B.:** The physiopathology of the disease induced in DBA/2 mice by MPSV. In: *In Vivo and In Vitro Erythropoiesis: The Friend System (G.B. Rossi, ed.)*, pp. 183-192. Elsevier/North Holland, Amsterdam, 1980.
68. **Ostertag, W., Pragnell, I.B., Fagg, B., Jovin, T.M., Grimwade, B.G., and Arndt-Jovin, D.J.:** Cell cycle dependent events during Friend cell differentiation. In: *In Vivo and In Vitro Erythropoiesis: The Friend System (G.B. Rossi, ed.)*, pp. 261-271. Elsevier/North Holland, Amsterdam, 1980.
69. **Pragnell, I.B., Colletta, G., Frisby, D., Seliger, B., Ostertag, W., Warnecke, G., Koch, G., and Bilello, J.:** Genomic and subgenomic expression of the SFFV genome in infected and erythroleukemia cells. In: *In Vivo and In Vitro Erythropoiesis: The Friend System (G.B. Rossi, ed.)*, pp. 333-346. Elsevier/North Holland, Amsterdam, 1980.
70. **Goldfarb, P., Ostertag, W., Conkie, D., Eskdale, J., Colletta, G., Frisby, D., and Harrison, P.:** Erythroid differentiation and Friend virus expression in Friend cell hybrids. In: *In Vivo and In Vitro Erythropoiesis: The Friend System (G.B. Rossi, ed.)*, pp. 383-390. Elsevier/North Holland, Amsterdam, 1980.
71. **Klein, B., LeBousse, C., Fagg, B., Smadja-Joffe, F., Vehmeyer, K., Mori, J., Jasmin, C., and Ostertag, W.:** Effects of myeloproliferative sarcoma virus on the pluripotential stem cell and granulocyte precursor cell populations of DBA/2 mice. *J. Natl. Cancer Inst.* **66**, 935-940 (1981).
72. **Ostertag, W., Odaka, T., Smadja-Joffe, F., and Jasmin, C.:** Inheritance of susceptibility to the myeloproliferative sarcoma virus: effect of the Fv-2 locus and evidence for a myeloproliferative sarcoma virus resistance locus. *J. Virol.* **37**, 541-548 (1981).
73. **LeBousse, M.C., Jasmin, C., Smadja-Joffe, F., Klein, B., Pragnell, I.B., and Ostertag, W.:** Myeloproliferative sarcoma virus (MPSV), a new tool for the study of hematopoiesis. *Blood Cells* **7**, 105-123 (1981).

74. **Pragnell, I.B., Fusco, A., Arbuthnott, C., Smadja-Joffe, F., Klein, B., Jasmin, C., and Ostertag, W.:** Analysis of the MPSV genome: limited changes in the prototype lead to altered target cell specificity. *J. Virol.* **38**, 952-957 (1981).
75. **Yamaguchi, Y., Kluge, N., Ostertag, W., and Furusawa, M.:** Erythroid differentiation and commitment in rat erythroleukemia cells with hypertonic culture conditions. *Proc. Natl. Acad. Sci. USA* **78**, 2325-2329 (1981).
76. **Greiser-Wilke, I., Ostertag, W., Goldfarb, P., Lang, A., Furusawa, M., and Conscience, J.F.:** Inducibility of spleen focus-forming virus by BUdR is controlled by the differentiated state of the cell. *Proc. Natl. Acad. Sci. USA* **78**, 2995-2999 (1981).
77. **Ostertag, W., and Pragnell, I.B.:** Differentiation and viral involvement in differentiation of transformed mouse and rat erythroid cells (Review). *Curr. Top. Microbiol. Immunol.* **94/95**, 143-208 (1981).
78. **Greiser-Wilke, I., Steinheider, G., Jentsch, E., Arndt-Jovin, D., Kluge, N., Eibl, H.J., and Ostertag, W.:** Co-expression of mouse and rat haemoglobins in interspecific hybrids of mouse and rat erythroleukemia cells. *Leukemia Res.* **6**, 9-15 (1982).
79. **Mol, J.N.M., Ostertag, W., Bilello, J., and Stoof, T.J.:** Rauscher spleen focus forming virus: biological properties and relationship to helper viruses. *J. Gen. Virol.* **63**, 45-56 (1982).
80. **Ostertag, W., Pragnell, I.B., Fusco, A., Hughes, D., Freshney, M., Klein, B., Jasmin, C., Bilello, J., Warneke, G., and Vehmeyer, K.:** Studies on the biology and genetics of murine erythroleukemia viruses. *In: Expression of Differentiated Functions in Cancer Cells (R. Revoltella, ed.)*, pp. 401-416. Raven Press, New York, 1982.
81. **Fagg, B., and Ostertag, W.:** Friend erythroleukemia virus complex: role of viral components modifying erythroid differentiation in mice. *J. Natl. Cancer Inst.* **68**, 457-460 (1982).
82. **Klein, B., LeBousse-Kerdiles, M.C., Smadja-Joffe, F., Pragnell, I., Ostertag, W., and Jasmin, C.:** A study of added CM-CSF independent granulocyte and macrophage precursors in mouse spleen infected with a myeloproliferative sarcoma virus (MPSV). *Exp. Hematol.* **10**, 373-382 (1982).
83. **Fagg, B., Ostertag, W., Klein, B., and LeBousse, C.:** Myeloproliferative sarcoma virus: its effects on erythropoiesis in adult DBA/2J mice. *J. Cell. Physiol.* **116**, 16-20 (1983).
84. **LeBousse-Kerdiles, M.C., Smadja-Joffe, F., Klein, B., Jasmin, C., Comisso, M., and Ostertag, W.:** Myeloproliferative syndrome induced by MPSV in DBA/2 mice: presence of a mixed-colonies promoting activity (MPA) in the spleen. *Blood* **61**, 520-524 (1983).
85. **Mori, K.J., Smadja-Joffe, F., Barre-Sinoussi, F., LeBousse-Kerdiles, M.C., Klein, B., Caillou, B., Ostertag, W., Jasmin, C., and Degiorgis, V.:** Myeloproliferative sarcoma virus stimulates pluripotent hematopoietic stem cells and provokes tumoral transformation of the hematopoietic microenvironment *in vitro*. *Leukemia Res.* **7**, 77-86 (1983).
86. **Ostertag, W., Freshney, M., Vehmeyer, K., Jasmin, C., and Rutter, G.:** Action of temperature-sensitive mutants of myeloproliferative sarcoma virus suggests that fibroblast-transforming and hematopoietic transforming viral properties are related. *J. Virol.* **49**, 173-181 (1984).
87. **Asche, W., Colletta, G., Warnecke, G., Nobis, P., Pennie, S., King, R.B., and Ostertag, W.:** Lack of retrovirus gene expression in somatic cell hybrids between Friend

- cells and teratocarcinoma cells with a teratocarcinoma phenotype. *Mol. Cell. Biol.* **4**, 923-930 (1984).
88. **Kollek, R., Stocking, C., Smadja-Joffe, F., and Ostertag, W.:** Molecular cloning and characterization of a leukemia inducing myeloproliferative sarcoma virus and two of its temperature-sensitive mutants. *J. Virol.* **50**, 717-724 (1984).
89. **Stacey, A., Arbuthnott, C., Kollek, R., Coggins, L., and Ostertag, W.:** Comparison of myeloproliferative sarcoma virus with Moloney murine sarcoma virus variants by nucleotide sequencing and heteroduplex analysis. *J. Virol.* **50**, 725-732 (1984).
90. **Yamasaki, H., Martel, N., Fusco, A., and Ostertag, W.:** Continuous suppression of globin gene expression and differentiation of Friend erythroleukemia cells by phorbol 12-myristate 13-acetate (PMA) despite the loss of PMA binding sites by down regulation. *Proc. Natl. Acad. Sci. USA* **81**, 2075-2079 (1984).
91. **Stacey, A.J., Kollek, R., Stocking, C., LeBousse-Kerdiles, M.C., Smadja-Joffe, F., Franz, T., Friel, J., Arbuthnott, C., and Ostertag, W.:** Studies on the biology and genetics of murine erythroleukemia viruses. II. Molecular biology of MPSV. *In: Expression of Differentiated Functions in Cancer Cells (R. Revoltella, ed.)*, Alan Liss, New York, 1984.
92. **Hess, N., Franz, T., Kollek, R., and Ostertag, W.:** Molecular cloning of Rauscher spleen focus forming virus and biological properties of the cloned virus. *J. Gen. Virol.* **65**, 2225-2235 (1984).
93. **Kollek, R., Ostertag, W., Stocking, C., and Stacey, A.:** Genomic structure and function of the murine myeloproliferative sarcoma virus. *Oncogene Symposium*, Florence, Italy, 1984.
94. **Johnson, G.R., Ostertag, W., and Nicola, N.A.:** Proliferation *in vivo* and *in vitro* of haemopoietic progenitor cells induced by AF-1, a new ras-containing retrovirus. *In: Modern Trends in Human Leukemia (R. Neth, ed.)*, Vol. 6, pp. 376-379, 1985.
95. **Franz, T., Löhler, J., Fusco, A., Pragnell, I., Nobis, P., Padua, R., and Ostertag, W.:** Transformation of mononuclear phagocytes *in vivo* and malignant histiocytosis caused by a novel murine spleen focus-forming virus. *Nature* **315**, 149-151 (1985).
96. **Stocking, C., Kollek, R., Bergholz, U., and Ostertag, W.:** Long terminal repeat sequences impart hematopoietic transformation properties to the myeloproliferative sarcoma virus. *Proc. Natl. Acad. Sci. USA* **82**, 5746-5750 (1985).
97. **Franz, T., Hilberg, F., Seliger, B., Stocking, C., and Ostertag, W.:** Retroviral mutants efficiently expressed in embryonal carcinoma cells. *Proc. Natl. Acad. Sci. USA* **83**, 3292-3296 (1986).
98. **Stocking, C., Kollek, R., Bergholz, U., and Ostertag, W.:** Point mutations in the U3 region of the long terminal repeat of Moloney murine leukemia virus determine disease specificity of the myeloproliferative sarcoma virus. *Virology* **153**, 145-149 (1986).
99. **Seliger, B., Kollek, R., Stocking, C., Franz, T., and Ostertag, W.:** Viral transfer, transcription, and rescue of a selectable myeloproliferative sarcoma virus in embryonal cell lines: expression of the *mos* oncogene. *Mol. Cell. Biol.* **6**, 286-293 (1986).
100. **Kluge, N., Ostertag, W., Fusco, A., Pennie, S., and Greenberger, J.S.:** Multipotential hemopoietic cell lines infected with Friend virus complex show presence of MuLV but not F-SFFV. *Leukemia Res.* **10**, 187-193 (1986).
101. **Ostertag, W.:** Onkogene und ihre Bedeutung während der Entstehung von malignen Tumoren. *In: Aktuelle Probleme der Biomedizin*, pp. 161-179. *Verlag de Gruyter & Co.*, Berlin, New York, 1986.
102. **Ostertag, W.:** Gentechnologie und ihre Anwendungsbereiche: Somatische Gentherapie und Diagnose ererbter und somatisch neu entstandener genetischer Defekte. *In: Chan-*

- cen und Risiken der Bio- und Gentechnologie (Hrsg.: Vorstand der SPD-Bürgerschaftsfraktion), pp. 72-82 (1986).*
103. **Ostertag, W., Seliger, B., Kollek, R., Stocking, C., Bergholz, U., and Smadja-Joffe, F.:** The myeloproliferative sarcoma virus retains transforming functions after introduction of a dominant selectable marker gene. *J. Gen. Virol.* **67**, 1361-1371 (1986).
 104. **Löhler, J., Franz, T., Klingler, K., Ostertag, W., and Padua, R.:** Retrovirus-induced malignant histiocytosis in mice: a model for the human disease. In: *Modern Trends in Human Leukemia (R. Neth and R.C. Gallo, eds)*, Vol. 7, pp. 448-449. Springer-Verlag, Heidelberg, 1987.
 105. **Löhler, J., Franz, T., Fusco, A., Pragnell, I., and Ostertag, W.:** Murine retrovirus-induced malignant histiocytosis, an experimental model for the disease in humans. *Leukemia* **1**, 58-68 (1987).
 106. **Hunt, N., Laker, C., Stocking, C., Heß, N., Nobis, P., Sieb, J., and Ostertag, W.:** Retroviral vectors for gene transfer into and gene expression in hematopoietic cells. *NATO Advanced Research Workshop "Molecular and Cellular Aspects of Erythropoiesis" (I.N. Rich, ed.)*, pp. 103-121. Springer-Verlag, 1987.
 107. **Friel, J., Stocking, C., Stacey, A., and Ostertag, W.:** A temperature-sensitive mutant of the myeloproliferative sarcoma virus, altered by point mutation in the *mos* oncogene, has been modified as a selectable retroviral vector. *J. Virol.* **61**, 889-897 (1987).
 108. **Hilberg, F., Stocking, C., Ostertag, W., and Grez, M.:** Functional analysis of a retroviral host range mutant: altered long terminal repeat sequences allow expression in embryonal carcinoma cells. *Proc. Natl. Acad. Sci. USA* **84**, 5232-5236 (1987).
 109. **Klingler, K., Johnson, G.R., Walker, F., Nicola, N.A., Decker, T., and Ostertag, W.:** Macrophage cell lines transformed by the malignant histiocytosis sarcoma virus. Increase of CSF receptors suggests a model for transformation. *J. Cell. Physiol.* **132**, 22-32 (1987).
 110. **Laker, C., Stocking, C., Bergholz, U., Hess, N., DeLamarter, J.F., and Ostertag, W.:** Autocrine stimulation after transfer of the granulocyte / macrophage colony-stimulating factor gene and autonomous growth are distinct but interdependent steps in oncogenic pathway. *Proc. Natl. Acad. Sci. USA* **84**, 8458-8462 (1987).
 111. **Ostertag, W., Stocking, C., Johnson, G.R., Kluge, N., Kollek, R., Franz, T., and Hess, N.:** Transforming genes and target cells of murine spleen focus forming viruses. *Adv. in Cancer Res.* **48**, 193-355 (1987).
 112. **Weiherr, H., Barklis, E., Ostertag, W., and Jaenisch, R.:** Two distinct sequence elements mediate retroviral gene expression in embryonal carcinoma cells. *J. Virol.* **61**, 2742-2746 (1987).
 113. **Stocking, C., Lölliger, C., Kawai, M., Suci, S., Gough, N., and Ostertag, W.:** Identification of genes involved in growth autonomy of hematopoietic cells by analysis of factor-independent mutants. *Cell* **53**, 869-879 (1988).
 114. **Klingler, K., Johnson, G.R., Nicola, N.A., Arman, G., Kluge, N., and Ostertag, W.:** Transformation of single myeloid cells by the malignant histiocytosis sarcoma virus (MHSV): generation of growth factor independent myeloid colonies and permanent cell lines. *J. Cell. Physiol.* **135**, 32-38 (1988).
 115. **Ostertag, W., Beck-Engeser, G., Stocking, C., Laker, C., Kluge, N., Dexter, M., and Spooner, E.:** Retroviral gene transfer into hematopoietic precursor and stem cells: initiation of leukemogenic progression. In: *Diagnostische und therapeutische Entwicklungen in der Hämatologie und Onkologie (K. Wilms, H. Rückle und P. Meyer, Hrsg.)*, pp. 43-60. W. Zuckschwerdt Verlag, München, 1988.

116. **Klingler, K., Laker, C., Stocking, C., Just, U., Kluge, N., Ostertag, W., Spooncer, E., Katsuno, M., and Dexter, M.:** Retroviral mediated transfer of growth factor genes into hemopoietic cells: a model for leukemogenesis. *In: Gene Transfer and Gene Therapy (A.L. Beaudet, R. Mulligan, and I.M. Verma, eds)*, pp. 79-88. A. Liss, New York, 1989.
117. **Ostertag, W.:** Retroviraler Gentransfer und somatische Gentherapie. *Universität Hamburg, Forschung* **23**, 45-48 (1989).
118. **Grez, M., and Ostertag, W.:** Control of retrovirus gene expression in mouse embryonal carcinoma cells. *Biol. Zentralbl.* **108**, 113-121 (1989).
119. **Grez, M., Akgün, E., Hilberg, F., Ziegler, M., and Ostertag, W.:** Identification of retroviral sequences involved in the inactivation of the viral genome in embryonal carcinoma cells. *In: Vectors as Tools for the Study of Normal and Abnormal Growth and Differentiation (H. Lothar, R. Dernick, and W. Ostertag, eds)*, pp. 95-111. *NATO ASI Series Vol. H 34: Cell Biology*. Springer-Verlag, Berlin, Heidelberg, New York (1989).
120. **Just, U., Spooncer, E., Katsuno, M., Hampson, I., Dexter, M., DeLamarter, J.F., Stocking, C., Kluge, N., and Ostertag, W.:** Infection of multipotent IL-3 dependent stem cells with a retroviral vector containing the IL-3 gene confers density dependent growth autonomy without blocking differentiation. *In: Modern Trends in Human Leukemia VIII (R.D. Neth et al., eds)*, pp. 197-205. Springer-Verlag, Heidelberg, 1989.
121. **Laker, C., Stocking, C., Kluge, N., Franz, M.J., Beck-Engeser, G., Spooncer, E., Dexter, M., and Ostertag, W.:** Aberrant expression of the multi-CSF gene in hematopoietic precursor and stem cell lines initiates leukemogenic progression. *In: Modern Trends in Human Leukemia (R. Neth et al., eds)*, pp. 188-205. Springer-Verlag, Heidelberg, 1989.
122. **Laker, C., Kluge, N., Stocking, C., Just, U., Franz, M.J., Ostertag, W., DeLamarter, J.F., Dexter, M., and Spooncer, E.:** Rates of mutation to growth factor autonomy and tumorigenicity differ in hematopoietic stem and precursor cells expressing the multilineage colony-stimulating factor gene. *Mol. Cell. Biol.* **9**, 5746-5749 (1989).
123. **Lothar, H., Dernick, R. and Ostertag, W. (eds):** Why a Workshop on Vectors as Tools for the Study of Normal and Abnormal Growth and Differentiation? *NATO ASI Series, Vol. H 34: Cell Biology*. Springer-Verlag, Berlin, Heidelberg, New York (1989).
124. **Spooncer, E., Katsuno, M., Hampson, I., Dexter, T.M., Just, U., Stocking, C., Kluge, N., and Ostertag, W.:** Biological effects of retroviral transfection of the murine Interleukin-3 gene into FDC P-Mix cells. *Curr. Top. Microbiol. Immunol.* **149**, 109-116 (1989).
125. **Stocking, C., Kawai, M., Laker, C., Löliger, C., Kluge, N., Klingler, K., and Ostertag, W.:** Conversion of factor-dependent myeloid cells to factor independence: autocrine stimulation is not coincident with tumorigenicity. *Curr. Top. Microbiol. Immunol.* **149**, 117-126 (1989).
126. **Wessel, K., Kaever, V., Ostertag, W., and Resch, K.:** A virus-transformed macrophage-like cell line as tool for eicosanoid research. *J. Leukocyte Biol.* **46**, 476-483 (1989).
127. **Fiedler, W., Suci, E., Wittlief, C., Ostertag, W., and Hossfeld, D.K.:** Mechanisms of growth factor expression in acute myeloid leukemia (AML). *Leukemia* **4**, 459-461 (1990).
128. **Friel, J., Hughes, D., Pragnell, I., Stocking, C., Laker, C., Nowock, J., Ostertag, W., and Padua, R.A.:** The malignant histiocytosis sarcoma virus, a recombinant of Harvey murine sarcoma virus and Friend mink cell focus-forming virus, has acquired

- myeloid transformation specificity by alterations in the long terminal repeat. *J. Virol.* **64**, 369-378 (1990).
129. **Grez, M., Akgün, E., Hilberg, F., Ziegler, M., and Ostertag, W.:** Retroviral expression in murine stem cells. In: *Recombinant Systems in Protein Expression* (K.K. Alitalo *et al.*, eds), pp. 149-165. Elsevier Publications, 1990.
130. **Grez, M., Akgün, E., Hilberg, F., and Ostertag, W.:** Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. *Proc. Natl. Acad. Sci. USA* **87**, 9202-9206 (1990).
131. **Heberlein, C., Kawai, M., Franz, M.-J., Beck-Engeser, G., Daniels, P., Ostertag, W., and Stocking, C.:** Retrotransposons as mutagens in the induction of growth autonomy in hematopoietic cells. *Oncogene* **5**, 1799-1807 (1990).
132. **Laker, C., Gräning, G., Kelso, A., Stocking, C., and Ostertag, W.:** Abrogation of the requirement for feeder cell interaction and T cell receptor stimulation of lymphocytes infected with retroviral vectors. *J. Exp. Med.* **172**, 447-456 (1990).
133. **Phi-Van, L., von Kries, J.P., Ostertag, W., and Strätling, W.H.:** The chicken lysozyme 5' matrix attachment region increases transcription from a heterologous promoter in heterologous cells and dampens position effects on the expression of transfected genes. *Mol. Cell. Biol.* **10**, 2302-2307 (1990).
134. **Spooner, E., Dexter, M., Ostertag, W., and Clark, G.J.:** Biological effects of interleukin-3, mutated N-ras and c-myc genes in primitive haematopoietic cells. In: *Molecular Biology of Haematopoiesis* (L. Sachs, N.G. Abraham, C.J. Wiedermann, A.S. Levine and G. Konwalinka, eds), pp. 483-494. Intercept Ltd, Andover, Hampshire, UK, 1990.
135. **Stocking, C., Laker, C., Heberlein, C., Kawai, M., Franz, M.-J., Just, U., Spooner, E., Beck-Engeser, G., and Ostertag, W.:** Retroviruses as tools to study the genes regulating normal and aberrant haematopoiesis. In: *Molecular Biology of Haematopoiesis* (L. Sachs, N.G. Abraham, C.J. Wiedermann, A.S. Levine and G. Konwalinka, eds), pp. 495-512. Intercept Ltd, Andover, Hampshire, UK, 1990.
136. **Stocking, C., and Ostertag, W.:** Interleukin 3: a multi-lineage hematopoietic growth factor. In: *Growth Factors, Differentiation Factors, and Cytokines* (A. Habenicht, ed.), pp. 115-129. Springer-Verlag, Heidelberg, 1990.
137. **Amagai, T., Hitomi, S., Sakai, Y., Komatsubara-Takagi, S., Stocking, C., and Ostertag, W.:** Establishment of Schwann cell lines by oncogene transfer. *Mol. Cell. Neurosci.* **2**, 6-12 (1991).
138. **Beck-Engeser, G., Stocking, C., Just, U., Spooner, E., Dexter, M., and Ostertag, W.:** Retroviral vectors related to the myeloproliferative sarcoma virus allow efficient expression in hematopoietic stem and progenitor cells. *Hum. Gene Ther.* **2**, 61-70 (1991).
139. **Dube, S.K., and Ostertag, W.:** AZT before AIDS. *Nature* **352**, 114 (1991).
140. **Just, U., Stocking, C., Spooner, E., Dexter, T.M., and Ostertag, W.:** Expression of the GM-CSF gene after retroviral transfer in hematopoietic stem cell lines induces synchronous granulocyte-macrophage differentiation. *Cell* **64**, 1163-1173 (1991).
141. **Ostertag, W.:** Inhibierende Wirkung von Azidothymidin auf Retrovirusfreisetzung und Replikation. In: *Festschrift zum Heinz Ansmann Preis*, Düsseldorf (1991).
142. **Gäken, J., Stocking, C., Ostertag, W., and Farzanah, F.:** Construction of a set of versatile retroviral vectors conferring hygromycin resistance. *Bio Technique* **13**, 32-33 (1992).
143. **Just, U., Heberlein, C., Baccarini, M., Friel, J., and Ostertag, W.:** Lineage specific receptors are upregulated in myeloid stem cells during differentiation induced by GM-

- CSF: Implications for the Hybrid Model of differentiation. *In: 2nd International Symposium "Molecular Biology of Hematopoiesis" 2*, 155-166 (1992).
144. **Singh, B., Stocking, C., Walker, R., Yang, Y., Ostertag, W., and Arlinghaus, R.B.:** v-mos proteins encoded by myeloproliferative sarcoma virus and its ts159 mutant. *J. Virol.* **66**, 1267-1272 (1992).
145. **Wiktor-Jedrzejczak, W., Ratajczak, M.Z., Ptasznik, A., Sell, K.W., Ahmed-Ansari, A., and Ostertag, W.:** CSF-1 deficiency in the op/op mouse has differential effects on macrophage populations and differentiation stages. *Exp. Hematol.* **20**, 1004-1010 (1992).
146. **Hibi, S., Löhler, J., Friel, J., Stocking, C., and Ostertag, W.:** Induction of monocytic differentiation and tumorigenicity by v-Ha-ras in differentiation-arrested hematopoietic cells. *Blood* **81**, 1841-1848 (1993).
147. **Just, U., Friel, J., Heberlein, Chr., Tamura, T., Baccarini, M., Tessmer, U., Klingler, K., and Ostertag, W.:** Upregulation of lineage specific receptors and ligands in multipotential progenitor cells is part of an endogenous program differentiation. *Growth Factors* **9**, 291-300 (1993).
148. **Just, U., Katsuno, M., Stocking, C., Spooncer, E., and Dexter, M.:** Targeted in vivo infection with a retroviral vector carrying the interleukin-3 (multi-CSF) gene leads to immortalization and leukemic transformation of primitive hematopoietic progenitor cells. *Growth Factors* **9**, 44-45 (1993).
149. **Nibbs, R.J.B., Itoh, K., Ostertag, W., and Harrison, P.R.:** Differentiation arrest and stromal cell-independent growth of murine erythroleukemia cells are associated with elevated expression of *ets*-related genes, but not with mutation of *p53*. *Mol. Cell Biol.* **13**, 5582-5592 (1993).
150. **Stocking, C., Bergholz, U., Friel, J., Klingler, K., Wagener, T., Starke, Chr., Kitamura, T., Miyajima, A., and Ostertag, W.:** Distinct classes of factor-independent mutants can be isolated after retroviral mutagenesis of a human myeloid stem cell line. *Growth Factors* **8**, 197-209 (1993).
151. **Stocking, C., Grez, M., and Ostertag, W.:** Regulation of retrovirus infection and expression in embryonic and hematopoietic stem cells. *In: Symposium "Virus Strategies" (W. Doerfler, ed.)*, Verlag Chemie, Weinheim, 433-455 (1993).
152. **Ahlers, N., Hunt, N., Just, U., Laker, C., Ostertag, W., and Nowock, J.:** Selectable retroviral vectors encoding Friend virus gp55 or erythropoietin induce polycythemia with different phenotypic expression and disease progression. *J. Virol.* **68**, 7235-7243 (1994).
153. **Heusohn, F., Pohler, U., Decker, T., Just, U., Ostertag, W., Lohmann-Matthes, M.L. & Baccarini, M.:** Coordinate expression of the lineage-specific growth factor CSF-1 and its receptor selectively promotes macrophage maturation during differentiation of multipotential progenitor cells. *Cell growth and Differentiation* **5**, 1119-1126 (1994).
154. **Just, U., Spooncer, E., Löhler, J., Stocking, C., Ostertag, W. and Dexter, T.M.:** Mutants of a multipotent hematopoietic cell line blocked in GM-CSF- induced differentiation are leukemogenic *in vivo*. *Exp. Hematol.* **22**, 933-940 (1994).
155. **Baum, C. und Ostertag, W.:** Somatischer Gentransfer und Genterapie - Prinzipien und Perspektiven. *Deutsches Ärzteblatt* **91**, 3180-3184 (1994).

156. **Wiss. Beirat der Bundesärztekammer:** Richtlinien zum Gentransfer in menschliche Körperzellen. *Deutsches Ärzteblatt* **92**, A: 789-794, B: 583-588, C: 507-512 (1995).
157. **Baum, C., Hegewisch-Becker, S., Eckert, H. G., Stocking, C. and Ostertag, W.:** Novel retroviral vectors for efficient gene expression of the multidrug-resistance (mdr-1) gene in early hemopoietic cells. *J. Virology* **69**, 7541-47 (1995).
158. **Bergemann, J., Kühlcke, K., Fehse, B., Ratz, I., Ostertag, W. and Lothar, H.:** Excision of specific DNA-sequences from integrated retroviral vectors via site specific recombination. *Nucl. Acid Res.* **23**, 4451-56 (1995).
159. **Hannemann, J., Hara, T., Kawai, M., Miyajima, A., Ostertag, W., and Stocking, C.:** Sequential mutations in the IL3/GM-CSF/IL5 receptor β -subunit genes are necessary for the complete conversion to growth autonomy mediated by a truncated β_c -subunit. *Mol. Cell. Biol.* **15**, 2402-2412 (1995).
160. **Janssen, J. W. G., Ridge, S. A., Papadopoulos, P., Cotter, F., Ludwig, W. D., Fonatsch, C., Rieder, H., Ostertag, W., Bartram, C. R. and Wiedemann, L. M.:** The fusion of TEL and ABL in human lymphoblastic leukaemia is a rare event. *British J. of Haematology* **90**, 222-224, (1995)

161. **Helftenbein, G., Krusekopf, K., Just, U., Cross, M., Ostertag, W., Niemann, H., and Tamura, T.:** Transcriptional regulation of the c-fms protooncogene mediated by granulocyte/macrophage colony-stimulating factor (GM-CSF) in murine cell lines. *Oncogene* **12**, 931-935 (1996)

162. **Baum, C., Margison, G. P., Eckert, H. G., Fairbairn, L. A., Ostertag, W. and Rafferty, J. A.:** Gene transfer to augment the therapeutic index of anticancer chemotherapy. *Editorial, Gene Therapy* **3**, 1-3 (1996).
163. **Just, U., Ahlers, N., Arman, G., Hunt, N., Ostertag, W. and Nowock, J.:** Erythropoietin and the ENV gp55 of the spleen focus forming virus (SFFV) interact differently with erythroid cells in the mouse and in tissue culture. *In: Gene Technology (eds: A. Zander, W. Ostertag, B. Afanasiev and F. Grosveld.)*, NATO ASI Series **94**, 203-218, Springer-Verlag, Berlin-Heidelberg (1996).
164. **Baum, C., Eckert, H.-G. and Ostertag, W.:** Contribution of the retroviral leader to gene transfer and expression in packaging cells and myeloid stem and progenitor cells. *In: Gene Technology, (eds: A. Zander, W. Ostertag B. Afanasiev and F. Grosveld)*, NATO ASI Series **94**, 219-228, Springer-Verlag, Berlin-Heidelberg (1996).
165. **Fehse, B., Papadopoulos, P., Kühlcke, K., Bergemann, J., Ratz, I., Stocking, C., Ostertag, W. and Lothar, H.:** Cloning of retroviral insertion sites possibly involved in growth-factor autonomy. *In: Gene Technology, (eds: A. Zander, W. Ostertag, B. Afanasiev and F. Grosveld)*, NATO ASI Series **94**, 285-293, Springer-Verlag, Berlin-Heidelberg (1996).
166. **Laker, C., Friel, J., Franz, M.-J., Baccharini, M., Ostertag, W. and Stocking, C.:** Altered growth factor response in myeloid progenitor cell mutants derived after retroviral insertional mutagenesis. *In: Gene Technology (eds: A. Zander, W. Ostertag, B. Afanasiev and F. Grosveld)*, NATO ASI Series **94**, 307-319, Springer-Verlag, Berlin-Heidelberg (1996).
167. **Jelinek, J., Fairbairn, L., Dexter, M., Rafferty, J., Stocking, C., Ostertag, W., and Margison, G.P.:** Long-term protection of hematopoiesis against the cytotoxic effects of multiple doses of nitrosourea by retrovirusmediated expression of human O^6 -alkylguanine-DNA-alkyltransferase. *Blood* **87**, 1957-1961 (1996)

168. **Itoh, K., Friel, J., Kluge, N., Kina, T., Kondo-Takaori, A., Kawamata, S., Uchiyama, T. and Ostertag, W.:** A novel hemopoietic multi-lineage stem cell clone, Myl-D-7, is stroma cell dependent and supported by an alternative mechanism independent of stem cell factor/c-kit interaction. *Blood* **87**, 3218-3228 (1996)
169. **Baum, C. und Ostertag, W.:** Retrovirale Vektoren. *Forum* **11** (Deutsche Krebsgesellschaft), 198-204 (1996).
170. **Baum, C., Eckert, H. G., Stocking, C., and Ostertag, W.:** Activity of Friend mink cell focus-forming retrovirus during myelo-erythroid hematopoiesis. *Experimental Hematology* **24**, 364-370 (1996).
171. **Baum, C., Eckert, H. G., Stockschläder, M., Just, U., Hegewisch-Becker, S., Hildinger, M., Uhde, A., John, J., and Ostertag, W.:** Improved retroviral vectors for hematopoietic stem cell protection and *in vivo* selection. *J. of Hematotherapy* **5**, 323-329 (1996).
172. **Eckert, H.G., Stockschläder, M., Just, U., Hegewisch-Becker, S., Grez, M., Zander, A., Ostertag, W., and Baum, C.:** High-dose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral vectors. *Blood* **88**, 3407-3415 (1996).
173. **Stöcker, G., Drzeniek, Z., Just, U., Ostertag, W., Greiling, H., and Haubeck, H.-D.:** Proteoglycan synthesis in human and murine multipotent haematopoietic cell lines – Isolation and characterization of heparan sulphate proteoglycans as the major proteoglycans from the human haematopoietic cell line TF-1. *Biochem. J.* **317**, 203-212,(1996).
174. **Baum, C., and Ostertag, W.:** Somatischer Gentransfer in der Onkologie. In: *Onkologie*, W. J. Zeller, H. zur Hausen, *comed. Verlag*, Landsberg, 1-23 (1996).
175. **Margison, G.P., Hickson, I., Jelinek, J., Kelly, J., Elder, R.H., Rafferty, J.A., Fairbairn, L.J., Dexter, T.M., Stocking, C., Baum, C., Ostertag, W., Donnelly, D., McMurry, T.B.H., McCormick, J., and McElhinney, R.S.:** Resistance to alkylating agents: more or less. *Anti-Cancer Drugs* **7**, Suppl. 3, 109-116 (1996).
176. **Jelinek, J., Fairbairn, L.J., Dexter, T.M., Rafferty, J.A., Stocking, C., Baum, C., Ostertag, W., and Margison, G.P.:** Can Transfer of Drug Resistance Genes Improve the Tolerance of Hematopoietic Cells to Chemotherapy? *Casopis Lekaru Ceskych*, **136**, 22-26, (1997)
177. **Baum, C. and Ostertag, W.:** Lineage-Tropism of Murine Leukemia Virus Enhancer Activity within the Hematopoietic System. In: *ACUTE LEUKEMIAS VII*, **39**, 397-404, (eds: W. Hiddemann, T. Büchner, B. Wörmann, J.Ritter, U. Creutzig, M. Keating, W. Plunkett) Springer Verlag, Berlin-Heidelberg (1997).
178. **Baum, C., Itoh, K., Meyer, J., Laker, C., Ito, Y., and Ostertag, W.:** The Potent Enhancer Activity of the Polycythemic Strain of Spleen Focus-Forming Virus in Hematopoietic Cells Is Governed by a Binding Site for Sp 1 in the Upstream Control Region and by a Unique Enhancer Core-Motif, Creating an Exclusive Target for PEBP/Cbf. *J. Virol.* **71**, 6323-6331 (1997).
179. **Baum, C., Stocking, C., Wagener, T., Eckert, H.G., and Ostertag, W.:** Gene transfer and transgene expression in hematopoietic cells. in: *Concepts in Gene Therapy* (Baranger, Strauss eds.) Walter de Gruyter Verlag. 233- 266 (1997)
180. **Itoh, K., Friel, J., Laker, C., Zeller, W., Just, U., Bittner, S., Nibbs, R., Harrison, P. R., Nishikawa, S. I., Mori, K. J., and Ostertag, W.:** The role of soluble growth factors in inducing transient growth and clonal extinction of stroma-cell dependent erythroblastic leukemia cells. *Leukemia* **11**, 1753-1761 (1997).
181. **Hildinger, M., Ostertag, W and Baum, C.:** Ist eine Gentherapie für Diabetes mellitus in Sicht? *Diabetes Dialog* **2**, 14-17 (1997).

182. **Drzeniek, Z., Siebertz, B., Stöcker, G., Just, U., Ostertag, W., Greiling, H. and Haubeck, H.-D.:** Proteoglycan synthesis in haematopoietic cells: isolation and characterization of heparan sulphate proteoglycans expressed by the bone-marrow stromal cell line MS-5. *Biochem. J.* **327**, 473-480 (1997).
183. **Friel, J., Heberlein, C., Itoh, K. and Ostertag, W.:** Role of Stem Cell Factor (SCF) Receptor and the Alternative Forms of its Ligand (SCF) in the Induction of Long Term Growth by Stroma Cells. In: *18th Symposium of the IACRLRD, Kyoto. Leukemia* **11**, suppl. 3, 493-495 (1997).
184. **Harrison, P.R., Nibbs, R.J.B., Bartholomew, C., O'Prey, J., Qiu, J., Walker, M., Clark, A.-M., Leslie, N. and Ostertag, W.:** Molecular mechanism involved in long-term maintenance of erythroleukaemia cells by stromal cells. In: *18th Symposium of the IACRLRD, Kyoto. Leukemia* **11**, suppl. 3, 474-477 (1997).
185. **Fehse, B., Uhde, A., Fehse, N., Eckert, H.-G., Clausen, J., Rüger, R., Koch, S., Ostertag, W., Zander, A. and Stockschröder, M.:** Selective immunoaffinity-based enrichment of CD34⁺ cells transduced with retroviral vectors containing an intracytoplasmically truncated version of the human low-affinity nerve growth factor receptor (Δ L-NGFR) gene. *Human Gene Therapy* **8**, 1815-1824 (1997).
186. **Baum, C., Hunt, N., Hildinger, M., Eckert, H.-G., Zaehres, H., Richters, A., John, J., Löhler, J. and Ostertag, W.:** *Cis*-active elements of Friend spleen focus-forming virus: From disease induction to disease prevention. *Acta Haematol.* **99**, 156-164 (1998)
187. **Hildinger, M., Fehse, B., Hegewisch-Becker, S., John, J., Rafferty, J. R., Ostertag, W., and Baum, C.:** Dominant selection of hematopoietic progenitor cells with retroviral *mdr1*-coexpression vectors. *Human Gene Therapy* **9**, 33-42, (1998)
188. **Laker, C., Meyer, J., Schopen, A., Friel, J., Heberlein, C., Ostertag, W. and Stocking, C.:** Host *cis*-Mediated Extinction of a Retrovirus Permissive for Expression in Embryonal Stem Cells during Differentiation. *J. Virol.* **72**, 339-348, (1998)
189. **Meyer, J., Jücker, M., Ostertag, W. and Stocking, C.:** Carboxyl-truncated STAT5 β is generated by a nucleus-associated serine protease in early hematopoietic progenitors. *Blood* **91**, 1901-1908 (1998)
190. **Laer, D.v., Thomsen, S., Vogt, B., Donath, M., Kruppa, J., Rein, A., Ostertag, W. and Stocking, C.:** Entry of Amphotropic and 10A1 Pseudotyped Murine Retroviruses is Restricted in Hematopoietic Stem Cell Lines. *J. Virol.* **72**, 1424-1430, (1998)
191. **O'Prey, J., Leslie, N., Itoh, K., Ostertag, W., Bartholomew, C. and Harrison, P.R.:** Both Stroma and SCF maintain long-term Growth of ELM Erythroleukaemia Cells But Only Stroma Prevents Erythroid Differentiation In Response To Erythropoietin and IL-3⁺. *Blood* **91**, 1548-1555 (1998)
192. **Thomsen, S., Vogt, B., von Laer, D., Heberlein, C., Rein, A., Ostertag, W. and Stocking, C.:** Lack of functional Pit-1 and Pit-2 expression on hematopoietic stem cell lines. *ACTA Haematologica*, **99**, 148-155, (1998)
193. **Hildinger, M., Eckert, H.-G., Schilz, A. J., John, J., Ostertag, W. and Baum, C.:** FMEV vectors: both retroviral long terminal repeat and leader are important for high expression in hematopoietic cells. *Gene Therapy* **5**, 1575 - 1579 (1998)
194. **Drzeniek, Z., Stöcker, G., Siebertz, B., Just, U., Schroeder, T., Ostertag and Haubeck, H.-D.:** Heparan sulfate proteoglycan expression is induced during early erythroid differentiation of multipotent haematopoietic stem cells. *Blood* **93**, 2884 - 2897, (1999)
195. **Baum, C., Ostertag, W., Stocking, C. and von Laer, D.:** Retroviral Vector Design for Cancer Gene Therapy. In *Gene Therapy of Cancer (first edition)*, eds.: E. Lattime and S. Gerson. Academic Press, 51-76, (1999)

196. **Heberlein, C., Friel, J., Laker, C., v. Laer, D., Bergholz, U., Bögel, M., Ashman, L.K., Klingler, K., and Ostertag, W.:** Downregulation of the c-kit (stem cell factor receptor) in transformed hematopoietic precursor cells by stroma cells. *Blood* **93**, 554-563 (1999)
197. **Hildinger, M., Abel, K.L., Ostertag, W. and Baum, C.:** Design of 5' untranslated sequences in retroviral vectors developed for medical use. *J.Virol.* **73**, 4083 - 4089 (1999)
198. **Fehse, B., Kühlcke, K., Langer, A., Ostertag, W. and Lothar, H.:** Rapid and efficient cloning of proviral flanking fragments by kanamycin resistance gene complementation. *Nucl. Acids Research* **27**, 706 -707 (1999)
199. **Miletic, H., Bruns, M., Tsiakas, K., Vogt, B., Rezai, R., Baum, C., Kühlke, K., Cosset, F.-L., Ostertag, W., Lothar, H. and von Laer, D.:** Retroviral vectors pseudotyped with lymphocytic choriomeningitis virus. *J.Virol.* **73**, 6114-6116 (1999)
200. **Jelinek, J.A., Rafferty, R., Cmejla, M., Hildinger, M., Chinnasamy, W., Ostertag, W., Margison, G.P., Dexter, T.M., Fairbairn, L.J. and Baum, C.:** A novel dual function retrovirus expressing multidrug resistance-1 and O⁶-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents. *Gene Therapy* **6**,1489-1493 (1999)
201. **Hildinger, M., Schilz, A., Eckert, H.-G., Bohn, W., Fehse, B., Zander, A.R., Ostertag, W. and Baum, C.:** Bicistronic retroviral vectors for combining myeloprotection with cell surface marking. *Gene Therapy* **6**, 1222-1230, (1999)
202. **Baum, C., Richters, A. and Ostertag, W.:** Retroviral vector-mediated gene expression in hematopoietic cells. *Current Opinions in Molecular Therapeutics* **1**, 605 – 612 (1999)
203. **Danno, S., Itoh, K., Baum, C., Ostertag, W., Ohnishi, N., Kido, T., Tomiwa, K., Marsuda, T. and Fujita, J.:** Efficient Gene Transfer by Hybrid Retroviral Vectors to Murine Spermatogenic cell. *Human Gene Therapy* **10**, 1819-1831 (1999).
204. **Baum, C., Hildinger, M., Peinert, S., Carpinteiro, A., Richters, A., Ostertag, W., Hegewisch-Becker, S., Zander, A., Schilz, A: Kühlcke, K., Eckert, H.-G., Rafferty, J.R., Lashford, L.S. and Fairbairn, L.J.:** Prospects for intensified consolidation chemotherapy by genetic chemoprotection of hematopoietic cells. In : *High-dose therapy and transplantation of haematopoietic stem cells (Schutze,W., ed.)*, pp 111-121. Blackwell Wissenschafts-Verlag, Berlin (2000).
205. **Tsuji, T., Itoh, K., Baum, C., Ohishi, N., Tomiwa, K., Hirano, D., Nishimura, M., Ostertag, W. and Fujita, J.:** Retroviral Vector - Mediated Gene Expression in Human CD34⁺ CD38⁻ Cells Expanded in Vitro: Cis-Elements of FMEV Are Superior to Those of MoMLV. *Human Gene Therapy* **11**, 271-284 (2000)
206. **Baum, C., Hildinger, M. and Ostertag, W.:** Retroviral Transfer And Expression Of Drug Resistance Genes In Hematopoietic Cells. In: *Transplantation in Hematology and Oncology.* eds.: Büchner, Th. et al., Springer Verlag Berlin-Heidelberg. 279 - 286 (2000)
207. **Laker, C., Friel, J., Papadopoulos, P., Franz, M.J., Hara, T., Ostertag, W., and Stocking, C.:** Transcriptional activation of the granulocyte-macrophage colony-stimulating factor receptor gene in cell mutants. *Experimental Cell Research* **259**, 1-11(2000)
208. **Horn, P.A., Möhlig, M., Osterhoff, M., Hofmann, J., Stocking, C., Ostertag, W., Wahl, M., Schatz, H. and Pfeiffer, A.:** Effect of estradiol on insulin secreting ins-1 cells overexpressing estrogen receptors. *Europ. J. of Endocrinology* **142**, 84-91 (2000)
209. **Fehse, B., Richters, A., Putimtseva-Scharf, K., Klump, H., Li, Z., Ostertag, W., Zander, A.R. and Baum, C.:** CD34 splice variant: an attractive marker for selection of gene-modified cells. *Molecular Therapy* **1**, 448-456 (2000)

210. **von Laer, D., Corovic, A., Vogt, B., Fehse, B., Roscher, S., Rimek, A., Baum, C. and Ostertag, W.:** Loss of CD38 antigen on CD34⁺ CD38⁺ cells during short-term culture. *Leukemia* **14**, 947-948 (2000)
211. **Knipper, R., Kuehlcke, K., Schiedlmeier, B., Hildinger, M., Lindemann, C., Schilz, A.J., Fauser, A. A., Fruehauf, S., Zeller, W. J., Ostertag, W., Eckert, H.-G. and Baum, C.:** Improved post-transcriptional processing of an *MDR1*-retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells. *Gene Therapy* **8**, 239-246 (2001)
212. **Beyer, W., Miletic, H., Ostertag, W. and von Laer, D.:** Recombinant Expression of the Lymphocytic Choriomeningitis Virus (WE) Glycoproteins: A single amino acid makes the difference. *J. Virol.* **75**, 1061-1064 (2001)
213. **Klump, H., Schiedlmeier, B., Vogt, B., Ryan, M., Ostertag, W. and Baum, C.:** Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy. *Gene Therapy* **8**, 811-817 (2001)
214. **Prassolov, V., Meyer, J., Brandenburg, G., Hannemann, J., Bergemann, J., Ostertag, W. and Stocking, C.:** Functional identification of secondary mutations inducing autonomous growth in synergy with a truncated interleukin-3 receptor: Implications for multi-step oncogenesis. *Exp. Hematol.*, **29**, 756-765 (2001)
215. **Baum, C., Ostertag, W., Stocking, C. and von Laer, D.:** Retroviral Vector Design for Cancer Gene Therapy. In *Gene Therapy of Cancer (second edition)*., eds.: E. Lattime and S. Gerson. Academic Press, 3-29 (2001)
216. **Wahlers, A., Zipfel, P., Schwieger, M., Ostertag, W. and Baum, C.:** In vivo analysis of retroviral enhancer mutations in hematopoietic cells: SP1/EGR1 and ETS/GATA motifs contribute to LTR specificity, *J. Virol.* **76**, 303-312 (2002)
217. **Beyer, W. R., Westphal, W., Ostertag, W. and von Laer, D.:** Oncoretroviral and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration and broad host range. *J. Virol.* **76**, 1488-1495 (2002)
218. **Carpinteiro, A., Peinert, S., Ostertag, W., Zander, A.R., Hossfeld, D.K., Kuehlcke, K., Eckert, H.G., Baum, C. and Hegewisch-Becker, S.:** Genetic Protection of Repopulating Hematopoietic Cells with an Improved MDR1-Retrovirus Allows Administration of Intensified Consolidation Chemotherapy Following Stem Cell Transplantation. *Int. J. Cancer* **98**, 785-792 (2002)
219. **Li, Z., Düllmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., Ostertag, W., Kuehlcke, K., Eckert, H.-G., Fehse, B. and Baum, C.:** Murine leukemia induced by retroviral gene marking. *Science* **296**, 497 (2002)
220. **Friel, J., Itoh, K., Bergholz, U., Jücker, M., Stocking, C., Harrison, P. and Ostertag, W.:** Hierarchy of stroma-derived factors in supporting growth of stroma-dependent hemopoietic cells: membrane-bound SCF is sufficient to confer stroma competence to epithelial cells. *Growth Factors* **20**, 35-51 (2002)
221. **Will, E., Klump, H., Heffner, N., Schwieger, M., Schiedlmeier, B., Ostertag, W., Baum, C. and Stocking, C.:** Unmodified Cre recombinase crosses the membrane. *Nucleic Acid Res.* **12**, e59 (2002)
222. **Meyer, J., Laker, C., Janzir, N., Franz, M.-J., Bergholz, U., Ostertag, W. and Stocking, C.:** Activation of the gene for the PDGF receptor β (PDGFR β) after retroviral insertion mutagenesis of interleukin-3-dependent myeloid cells: implications for the transforming potential of PDGFR β . *Growth Factors* **20**, 131-140 (2002)

- 223 **Li, Z., Fehse, B., Schiedlmeier, B., Düllmann, J., Frank, O., Zander, A. A., Ostertag, W. and Baum, C.:** Persisting multilineage transgene expression in the clonal progeny of a hematopoietic stem cell. *Leukemia* **16**, 1655-63 (2002).
- 224 **Schiedlmeier, B., Klump, H., Will, E., Arman-Kalcek, G., Li, Z., Wang, Z., Rimek, A., Friel, J., Baum, C., and Ostertag W:** High level ectopic HOXB4 expression confers a profound *in vivo* competitive growth advantage to human cord blood CD34⁺ cells, but impairs lymphomyeloid differentiation. *Blood* **101**(5), 1759-68 (2003).
- 225 **Horn, S; Meyer, J; Stocking, C; Ostertag, W. & Jucker, M.:** An increase in the expression and total activity of endogenous p60(c-Src) in several factor-independent mutants of a human GM-CSF-dependent leukemia cell line (TF-1). *Oncogene* **22** (46), 7170-7180 (2003)
-).
- 226 **Frank, O., Rudolph, C., Heberlein, C., Von Neuhoff, N., Schroeck, E., Schambach, A., Schlegelberger, B., Fehse, B., Ostertag, W., Stocking, and C., Baum, C.** Tumor cells escape suicide gene therapy by genetic and epigenetic instability. *Blood* **104**(12), 3543-3549 (2004).
- 227 **Friel, J., Heberlein, C., Geldmacher, M., and Ostertag, W.:** Diverse isoforms of Colony-Stimulating Factor-1 have different effects on the development of stroma-dependent hematopoietic cells. *J Cell Physiol.* **204**(1):247-59 (2005).
- 228 **Pilat, S., Carotta, S., Schiedlmeier, B., Kamino, K., Mairhofer, A., P., Will, E., E., Modlich, U., Beug, H., Ostertag, W., Steinlein, P., Baum, and Klump, H.** HOXB4 enforces equivalent fates of ES cell-derived and adult hematopoietic cells. *Proc Nat Acad Sci* **102**(34): 12101-1206 (2005).
- 229 **Heberlein, C., Friel, J., Itoh, K., Medlock, E. S., Li, L., Nakayama, N., Stocking, C., Geldmacher, M., and Ostertag, W.:** Involvement of CSF-1 in generating a stroma-independent hematopoietic stem cell line. *J Cell Physiol.* **206**(2):556-562 (2006).
- 230 **Will, E., Speidel, Wang, Z., Ghiaur, G., Rimek, A., Schiedlmeier, B., Williams, D. A., Baum, C., Ostertag, W., and Klump, H.** HOXB4 Inhibits Cell Growth in a Dose-Dependent Manner and Sensitizes Cells Towards Extrinsic Cues. *Cell Cycle* **5**(1):14-22 (2006).
- 231 **Friel, J., Schiedlmeier, B., Geldmacher, M., and Ostertag, W.:** Stromal cells selectively reduce the growth advantage of human committed CD34⁺ hematopoietic cells ectopically expressing HOXB4. *Growth Factors* **24**(2): 97-105 (2006).

